Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.

Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, Pika T, Pour L, Radocha J, Scudla V, Svachova H, Hajek R.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):414-20. doi: 10.1016/j.clml.2011.03.024. Epub 2011 May 10.

PMID:
21859556
3.

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.

Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E, Dimopoulos MA.

Am J Hematol. 2013 Sep;88(9):765-70. doi: 10.1002/ajh.23504. Epub 2013 Jul 24.

4.

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.

Uaprasert N, Voorhees PM, Mackman N, Key NS.

Eur J Cancer. 2010 Jul;46(10):1790-9. doi: 10.1016/j.ejca.2010.03.007. Epub 2010 Apr 10. Review.

PMID:
20385482
5.

VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.

Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V, Guadagni F, Roselli M.

Thromb Haemost. 2016 Jan;115(1):143-51. doi: 10.1160/TH15-03-0259. Epub 2015 Sep 3.

PMID:
26336029
6.

Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.

Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.

Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.

7.

Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.

Wu SY, Yeh YM, Chen YP, Su WC, Chen TY.

Ann Hematol. 2012 Nov;91(11):1773-8. doi: 10.1007/s00277-012-1506-2. Epub 2012 Jun 17.

PMID:
22706703
8.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group.

Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.

PMID:
18094721
9.

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.

Int J Cancer. 2012 Sep 1;131(5):E636-42. doi: 10.1002/ijc.27387. Epub 2012 Jan 31.

10.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Zangari M, Fink L, Zhan F, Tricot G.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. doi: 10.1016/j.clml.2011.03.006. Epub 2011 Apr 8. Review.

PMID:
21575928
11.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ.

Blood. 2008 Dec 15;112(13):4924-34. doi: 10.1182/blood-2008-02-140434. Epub 2008 Sep 19.

12.

Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.

Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, Legnani C, Catalano L, Masini L, Tosi P, Gozzetti A, Cavo M.

Eur J Haematol. 2010 Jun;84(6):484-92. doi: 10.1111/j.1600-0609.2010.01434.x. Epub 2010 Feb 23.

PMID:
20192986
13.

Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.

Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M.

Pharmacoepidemiol Drug Saf. 2017 May;26(5):578-586. doi: 10.1002/pds.4180. Epub 2017 Feb 15.

PMID:
28198064
14.

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA.

Mayo Clin Proc. 2005 Dec;80(12):1568-74.

PMID:
16342649
15.

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.

Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H.

Hematol Oncol. 2017 Dec;35(4):711-718. doi: 10.1002/hon.2322. Epub 2016 Jul 13.

PMID:
27405747
16.

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ.

J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.

PMID:
21245421
17.

Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism.

Beckers MM, Ruven HJ, Haas FJ, Doevendans PA, ten Cate H, Prins MH, Biesma DH.

Eur J Intern Med. 2010 Aug;21(4):289-92. doi: 10.1016/j.ejim.2010.04.001. Epub 2010 Apr 28.

PMID:
20603037
18.

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U.

Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24.

PMID:
21347685
19.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaleteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Fermand JP, Moreau P.

Thromb Haemost. 2013 Oct;110(4):844-51. doi: 10.1160/TH13-02-0140. Epub 2013 Aug 1.

PMID:
23903204
20.

[Association between gene polymorphisms of methylenetetrahydrofolate reductase and plasma homocysteine in Uygur patients with venous thromboembolism].

Abudureheman K, Mahemuti A, Xia YN, Hu XM.

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Dec;40(12):1030-6. Chinese.

PMID:
23363719

Supplemental Content

Support Center